Focus on Diabetes

Host: Shira Johnson, MD

Guest: Anne Peters, MD

Guest: Donna Miller, MSN, FNP-C, CDE

Guest: Jana Conley

This activity explores new and emerging treatments for type 1 diabetes, including a dual sodium glucose transporter 1/2 inhibitor, and provides both clinician and patient perspectives on their use.

Host: Rishi P. Singh, MD

Guest: Arshad Khanani, MD

Guest: Ehud Ur, MD

Guest: David Boyer, MD

Therapeutic options for the treatment of DR and DME have expanded, and advancements in medical imaging technologies provide a wider scope of options for efficient, accurate and reproducible diagnosis and monitoring of ocular conditions. Likewise, diabetes management guidelines and strategies, including pharmacologic treatments and devices, have also evolved, underscoring the importance of cross-disciplinary education and communication, as well as a higher level of participation from the patient. Treatment and management strategies need to be determined that lower the burden of illness, lower the burden of treatment, and enhance outcomes and overall quality of life for patients.

Host: Rishi P. Singh, MD

Guest: Arshad Khanani, MD

Guest: Ehud Ur, MD

Guest: David Boyer, MD

Therapeutic options for the treatment of DR and DME have expanded, and advancements in medical imaging technologies provide a wider scope of options for efficient, accurate and reproducible diagnosis and monitoring of ocular conditions. Likewise, diabetes management guidelines and strategies, including pharmacologic treatments and devices, have also evolved, underscoring the importance of cross-disciplinary education and communication, as well as a higher level of participation from the patient. Treatment and management strategies need to be determined that lower the burden of illness, lower the burden of treatment, and enhance outcomes and overall quality of life for patients.

Host: Barnett Mennen, MD

Guest: Sarah Hallberg, MD

Carbohydrates are our main source of energy and provide important nutrients for good health. However, they are also the main culprit behind elevated blood sugar and are problematic for diabetic patients trying to control their blood sugar levels.

Host Dr. Barry Mennen sits down with Dr. Sarah Hallberg to talk about carbohydrate restriction as a key to successful weight loss programs. She prescribes that adherence to a low-carb, high-fat diet is vital to patients for controlling their diabetes, with the possibility of being able to come off medications over time.

Dr. Sarah Hallberg is the Medical Director at Virta Health and Founder of the Indiana University-Arnett Health Medical Weight Loss Program in Lafayette, Indiana.

Host: John J. Russell, MD

Guest: John (Jack) L. Leahy, MD

Diabetes is a major global health emergency, affecting approximately 415 million adults and contributing to five million deaths each year. Cardiovascular disease is a serious complication of type 2 diabetes mellitus (T2DM), contributing to the majority of morbidity and mortality in this population. In recent years, the cardiovascular impact of anti-diabetes medications has become the focus of research. Recent findings from long-term, large-scale, cardiovascular outcome trials of antihyperglycemic agents have shown that some T2DM treatments can provide cardiometabolic benefits beyond glycemic control and may open the door for more successful management. As a value added-resource, a specialized toolkit will also be included as a supplement to the webcast. The toolkit will provide reference materials including key publications for a deeper review of the data for clinicians as well as helpful information and resources for families and caregivers.

Host: John J. Russell, MD

Guest: Anne Peters, MD, CDE

Many patients with type 2 diabetes mellitus cannot be controlled with standard insulin agents due to obesity, insulin resistance, high risk of hypoglycemia, low adherence due to high injection burden, and the need for frequent glucose monitoring. Drs. Peters and Russell will review patient cases, and share practical information on concentrated insulins, including criteria for selection, switching strategies and dosing regimens, providing true practice-based learning particularly for clinicians in different geographic locations with high incidence rates of diabetes.

Host: John J. Russell, MD

Guest: Anne Peters, MD, CDE

Many patients with type 2 diabetes mellitus cannot be controlled with standard insulin agents due to obesity, insulin resistance, high risk of hypoglycemia, low adherence due to high injection burden, and the need for frequent glucose monitoring. Drs. Peters and Russell will review patient cases, and share practical information on concentrated insulins, including criteria for selection, switching strategies and dosing regimens, providing true practice-based learning particularly for clinicians in different geographic locations with high incidence rates of diabetes.

Host: Matt T. Rosenberg, MD

Guest: Monica E. Peek, MD, MPH, MSC

Attaining and maintaining glycemic control continues to be very difficult for patients with type 2 diabetes. Please join Drs. Matt T. Rosenberg and Monica E. Peek as they discuss these issues.

Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.

Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.

A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at [email protected].

Released 5/16/2017

Host: John J. Russell, MD

Guest: Wendy S. Lane, MD

In this interview, Dr. Lane will review the clinical evidence supporting combinations of GLP-1 receptor agonists with basal insulin for the treatment of type 2 diabetes.